title: Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
abstract: This study compared the efficacy of an H2-receptor antagonist (H2RA)- and a proton-pump inhibitor (PPI)-based triple regimen for the eradication of Helicobacter pylori infection. Chinese patients with H. pylori-associated gastritis or peptic ulcer were randomized to receive the H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin and 0.4 g metronidazole) or the PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin and 0.4 g metronidazole) both twice daily for 1 or 2 weeks. Successful eradication of H. pylori was determined by the 13C-urea breath test and gastric mucosa histology at least 4 weeks after completion of antibiotic therapy. Eradication rates were 56.0% and 76.9% for the 1-week H2RA- and PPI-based triple regimens, respectively, and 81.6% and 82.1% for the 2-week regimens, respectively. The H. pylori eradication rate for the 2-week H2RA regimen was significantly higher than that for the 1-week regimen, but there were no significant differences between the 1- and 2-week PPI regimens. The two regimens proved equally effective in eradicating H. pylori infection.
authors.affiliation: Peking University First Hospital, Beijing 100034, China. hufl@263.net
authors.forename: F L
authors.initials: FL
authors.lastname: Hu
authors.forename: J C
authors.initials: JC
authors.lastname: Jia
authors.forename: Y L
authors.initials: YL
authors.lastname: Li
authors.forename: G B
authors.initials: GB
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use; D002681:China; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000472:pathogenicity; D006635:Histamine H2 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D015738:Famotidine; D000658:Amoxicillin; D009853:Omeprazole